Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

Ming Cheng(University of Arizona), Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center), Morgan Huse(Memorial Sloan Kettering Cancer Center), Brian H. Santich(Memorial Sloan Kettering Cancer Center), Hong Xu(Jilin University), Mahiuddin Ahmed(Memorial Sloan Kettering Cancer Center)
OncoImmunology
May 5, 2016
Cited by 41


Related Papers